Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Get Rating) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 28,900 shares, an increase of 26.8% from the November 30th total of 22,800 shares. Approximately 0.3% of the company's shares are short sold. Based on an average trading volume of 20,200 shares, the short-interest ratio is presently 1.4 days.

Acurx Pharmaceuticals Price Performance

Shares of ACXP opened at $3.98 on Friday. The stock's 50-day moving average is $3.33 and its two-hundred day moving average is $3.53. The stock has a market cap of $46.14 million, a PE ratio of -3.72 and a beta of -0.73. Acurx Pharmaceuticals has a 12 month low of $2.33 and a 12 month high of $4.89.

Acurx Pharmaceuticals (NASDAQ:ACXP – Get Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.32) EPS for the quarter. On average, research analysts anticipate that Acurx Pharmaceuticals will post -1.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Semmax Financial Advisors Inc. lifted its stake in shares of Acurx Pharmaceuticals by 365.5% in the second quarter. Semmax Financial Advisors Inc. now owns 5,879 shares of the company's stock worth $28,000 after acquiring an additional 4,616 shares in the last quarter. Castle Wealth Management LLC acquired a new position in shares of Acurx Pharmaceuticals in the second quarter worth about $49,000. BlackRock Inc. lifted its stake in shares of Acurx Pharmaceuticals by 149.8% in the first quarter. BlackRock Inc. now owns 16,699 shares of the company's stock worth $55,000 after acquiring an additional 10,014 shares in the last quarter. Finally, Armistice Capital LLC acquired a new position in shares of Acurx Pharmaceuticals in the third quarter worth about $3,198,000. Institutional investors and hedge funds own 13.13% of the company's stock.

About Acurx Pharmaceuticals

(Get Rating)

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.

Featured Stories

• Get a free copy of the StockNews.com research report on Acurx Pharmaceuticals (ACXP)
• MarketBeat: Week in Review 12/26 – 12/30
• The Dogs Of Tech: It's Time For A Bite Of These Stocks
• Does This Acquisition Make Microsoft a Bear Market Buy?
• Is Kintara Therapeutics A Hidden Gem?
• Should You Warm up to Generac Stock for the Winter?

Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.